Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. [Review]

MedStar author(s):
Citation: American Journal of Cardiovascular Drugs. 21(5):499-512, 2021 Sep.PMID: 33369719Institution: MedStar Union Memorial HospitalForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Cardiovascular Diseases/co [Complications] | *Colchicine/tu [Therapeutic Use] | *Gout Suppressants/tu [Therapeutic Use] | *Gout/dt [Drug Therapy] | *Gout/et [Etiology] | Colchicine/ae [Adverse Effects] | COVID-19 | Febuxostat/ae [Adverse Effects] | Febuxostat/tu [Therapeutic Use] | Gout Suppressants/ae [Adverse Effects] | Humans | Hyperuricemia/dt [Drug Therapy] | Hyperuricemia/et [Etiology] | PandemicsYear: 2021Local holdings: Available online from MWHC library: 2001 - 2009ISSN:
  • 1175-3277
Name of journal: American journal of cardiovascular drugs : drugs, devices, and other interventionsAbstract: Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA 'black box' warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper.All authors: Bandyopadhyay D, Deedwania P, Fonarow GC, Ghosh RK, Gupta M, Hajra A, Kaul S, Klein A, Lavie CJ, Mamas M, Roddy EOriginally published: American Journal of Cardiovascular Drugs. 2020 Dec 28Fiscal year: FY2022Fiscal year of original publication: FY2021Digital Object Identifier: ORCID: Date added to catalog: 2020-12-31
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33369719 Available 33369719

Available online from MWHC library: 2001 - 2009

Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA 'black box' warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper.

English

Powered by Koha